Exalenz Bioscience Granted US Patent for Liver Application of Company’s BreathID Platform Technology
8/21/2013 9:25:22 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
JERSEY CITY, N.J.--(BUSINESS WIRE)--Exalenz Bioscience (TASE: EXEN), developer of advanced diagnostic systems that use the patient’s breath to assess gastrointestinal and liver conditions, announced today that the company was granted its first patent for a liver application of its technology. The patent was granted by the United States Patent and Trademark Office. Patent number 8,512,258 was granted to Exalenz for the BreathID Platform Technology’s method of evaluating the liver condition of a patient.
Help employers find you! Check out all the jobs and post your resume.
comments powered by